Zhang Keqian, Qin Hong, Pan Feng, Liu Enqiang, Liang Houjie, Ruan Zhihua
Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, China (mainland).
Department of Oncology, Qianjiang Central Hospital, Qianjiang, China (mainland).
Med Sci Monit. 2014 Dec 30;20:2830-6. doi: 10.12659/MSM.891318.
Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC.
We retrospectively reviewed patients with stage III-IV unresectable NSCLC from 1 January 2010 to 31 December 2013 at Southwest Hospital. They all received nedaplatin (80 mg/m2, nedaplatin group) or oxaliplatin (130 mg/m2, oxaliplatin group) combined with paclitaxel (175 mg/m2) or docetaxel (75 mg/m2) as first-line treatment.
There are 174 patients enrolled - 123 patients in the nedaplatin group and 51 patients in the oxaliplatin group. The objective response rates were 47.3% and 34.1% and the disease control rates were 87.5% and 79.5% in nedaplatin and oxaliplatin groups, respectively. The progression-free survival time was 10.4 months and 9.6 months (p=0.722) and the overall survival time was 18.5 months and 25.5 months in the nedaplatin and oxaliplatin groups, respectively (p=0.09). Total toxicity was greater in the oxaliplatin group (p=0.008), but there is no significant difference among ¾ grade adverse events between the 2 groups (P=0.595).
The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC.
奈达铂和奥沙利铂联合紫杉醇或多西他赛在晚期非小细胞肺癌（NSCLC）患者中均显示出强效活性，但尚无研究比较这两种化疗方案之间的差异。本研究的目的是评估和比较奈达铂或奥沙利铂联合紫杉醇和多西他赛在晚期NSCLC患者中的疗效和安全性。
我们回顾性分析了2010年1月1日至2013年12月31日在西南医院就诊的III-IV期不可切除NSCLC患者。他们均接受奈达铂（80mg/m²，奈达铂组）或奥沙利铂（130mg/m²，奥沙利铂组）联合紫杉醇（175mg/m²）或多西他赛（75mg/m²）作为一线治疗。
共纳入174例患者，其中奈达铂组123例，奥沙利铂组51例。奈达铂组和奥沙利铂组的客观缓解率分别为47.3%和34.1%，疾病控制率分别为87.5%和79.5%。奈达铂组和奥沙利铂组的无进展生存期分别为10.4个月和9.6个月（p=0.722），总生存期分别为18.5个月和25.5个月（p=0.09）。奥沙利铂组的总毒性更大（p=0.008），但两组之间3/4级不良事件无显著差异（P=0.595）。
奈达铂联合紫杉醇和多西他赛的疗效与奥沙利铂联合紫杉醇和多西他赛相同，且奈达铂的毒性作为晚期NSCLC患者的一线治疗耐受性良好。
